Corbus Pharmaceuticals Holdings

Corbus Pharmaceuticals Holdings is an American clinical-stage pharmaceutical company, focuses on the development and commercialization of various therapeutics to treat rare, chronic, and serious inflammatory and fibrotic diseases. The company was founded in 2009 and is based in Norwood, Massachusetts.
Corbus Pharmaceuticals Holdings stock price chart
vol.
change
P/E
Net profit
P/B
Book value
P/FCF
FCF
Yield
Growth potential

Corbus Pharmaceuticals Holdings balance sheet

Report period2018 2019 2020 2021 2022Q3 23
End date of the reporting period
Capitalization, $
Capitalization, $
Enterprise Value
Book Value
Shareholders Book Value
Current liabilities
Noncurrent liabilities
Total liabilities
Debt
Cash and cash equivalents
Net debt
Assets
Total ordinary shares
Ordinary share price

Corbus Pharmaceuticals Holdings cash flows

Report period2018 2019 2020 2021 2022Q3 23 TTM
End date of the reporting period
Sales
Gross profit
Operation Income
Earnings
Shareholders earnings
EBITDA
Operation Cashflow
Capital expenditure
Free Cash Flow
EPS

Corbus Pharmaceuticals Holdings multipliers

Report period2018 2019 2020 2021 2022Q3 23 TTM
P/E
E/P
P/B
P/S
P/FCF
L/A
Debt-To-Equity
Net Debt/EBITDA
EV/EBITDA

Corbus Pharmaceuticals Holdings profitability

Report period2018 2019 2020 2021 2022Q3 23 TTM
ROA
ROE
ROS
EBITDA Margin
Operating margin
Corbus Pharmaceuticals Holdings assets
Corbus Pharmaceuticals Holdings cash flows

Corbus Pharmaceuticals Holdings dividend policy

The company doesn't provide dividend

Corbus Pharmaceuticals Holdings shares

TickerNameTypeNominal valueISINPrice
CRBP:USCorbus Pharmaceuticals HoldingsCommon share-US21833P1030$34.94
Corbus Pharmaceuticals Holdings news
10.05.2022
Corbus Pharmaceuticals' GAAP loss for 3 months of 2022 was $9.437 million, down 41.3% from $16.065 million in the previous year. The company did not generate revenue in the period. In the same period last year, revenue was $647,824 thousand a year earlier.
Source: {source} pictogram ir.corbuspharma.com
Pictogram next
08.03.2022
Corbus Pharmaceuticals' GAAP loss for 2021 was $45.64 million, down 2.4 times from $111.269 million in the previous year. Revenue decreased 4.5 times to $0.882 million from $3.937 million a year earlier.
Source: {source} pictogram ir.corbuspharma.com
Pictogram next
15.11.2021
Corbus Pharmaceuticals Holdings' GAAP loss for 9M 2021 was $35.38 million, down 2.9 times from $102.658 million in the previous year. Revenue decreased 3.7 times to $0.882 million from $3.279 million a year earlier.
Source: {source} pictogram ir.corbuspharma.com
Pictogram next
12.08.2021
Corbus Pharmaceuticals' GAAP loss for 6M 2021 was $33.204 million, down 51% from $67.762 million in the previous year. Revenue decreased 61.7% to $0.784 million from $2.048 million a year earlier.
Source: {source} pictogram ir.corbuspharma.com
Pictogram next
All Corbus Pharmaceuticals Holdings news
General information
Company nameCorbus Pharmaceuticals Holdings
Tags#pharmacy, #biotechnology
SectorHealth Care / Pharmaceuticals, Biotechnology & Life Sciences / Pharmaceuticals / Pharmaceuticals
Business address500 River Ridge Drive Norwood, MA 02062 United States
Mailing address500 River Ridge Drive Norwood, MA 02062 United States
Websiteir.corbuspharma.com
Information disclosurewww.sec.gov